Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome

Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders characterized by low blood counts and a propensity to develop acute myeloid leukemia. The management of lowerrisk (LR) MDS with persistent cytopenias remains suboptimal. Eltrombopag, a thrombopoietin-receptor agonist, can improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Vicente, Alana, Patel, Bhavisha A., Gutierrez-Rodrigues, Fernanda, Groarke, Emma M., Giudice, Valentina, Lotter, Jennifer, Feng, Xingmin, Kajigaya, Sachiko, Weinstein, Barbara, Barranta, Evette, Olnes, Matthew J., Parikh, Ankur R., Albitar, Maher, Wu, Colin O., Shalhoub, Ruba, Calvo, Katherine R., Townsley, Danielle M., Scheinberg, Phillip, Dunbar, Cynthia E., Young, Neal S., Winkler, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716353/
https://www.ncbi.nlm.nih.gov/pubmed/33256377
http://dx.doi.org/10.3324/haematol.2020.249995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716353/
https://www.ncbi.nlm.nih.gov/pubmed/33256377
http://dx.doi.org/10.3324/haematol.2020.249995

Ejemplares similares